GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Cyclically Adjusted PS Ratio

Eli Lilly and Co (Eli Lilly and Co) Cyclically Adjusted PS Ratio : 25.42 (As of Apr. 27, 2024)


View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Eli Lilly and Co's current share price is $733.51. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $28.86. Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is 25.42.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

LLY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.48   Med: 4.9   Max: 27.17
Current: 25.42

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PS Ratio was 27.17. The lowest was 2.48. And the median was 4.90.

LLY's Cyclically Adjusted PS Ratio is ranked worse than
98.51% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs LLY: 25.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share data for the three months ended in Dec. 2023 was $10.349. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $28.86 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.92 7.43 11.14 13.57 20.20

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.57 12.48 16.73 18.76 20.20

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=733.51/28.86
=25.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=10.349/129.4194*129.4194
=10.349

Current CPI (Dec. 2023) = 129.4194.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 4.353 99.695 5.651
201406 4.585 100.560 5.901
201409 4.538 100.428 5.848
201412 4.786 99.070 6.252
201503 4.353 99.621 5.655
201506 4.672 100.684 6.005
201509 4.656 100.392 6.002
201512 5.048 99.792 6.547
201603 4.576 100.470 5.895
201606 5.098 101.688 6.488
201609 4.894 101.861 6.218
201612 5.414 101.863 6.879
201703 4.950 102.862 6.228
201706 5.510 103.349 6.900
201709 5.358 104.136 6.659
201712 3.127 104.011 3.891
201803 4.728 105.290 5.812
201806 5.421 106.317 6.599
201809 5.171 106.507 6.283
201812 5.520 105.998 6.740
201903 5.175 107.251 6.245
201906 6.096 108.070 7.300
201909 5.963 108.329 7.124
201912 6.678 108.420 7.971
202003 6.427 108.902 7.638
202006 6.037 108.767 7.183
202009 6.299 109.815 7.424
202012 8.137 109.897 9.582
202103 7.459 111.754 8.638
202106 7.403 114.631 8.358
202109 7.436 115.734 8.315
202112 8.642 117.630 9.508
202203 8.617 121.301 9.194
202206 7.186 125.017 7.439
202209 7.680 125.227 7.937
202212 8.069 125.222 8.339
202303 7.705 127.348 7.830
202306 9.208 128.729 9.257
202309 10.556 129.860 10.520
202312 10.349 129.419 10.349

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (NYSE:LLY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (Eli Lilly and Co) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017